Reading Time: 5 minutesThe 35th International Symposium on ALS/MND, organised by the MND Association, was held on 6-8 December 2024 and welcomed over 1200 delegates to Montreal, Canada
Category: News
Reading Time: 7 minutesResearchers from the University of Aberdeen and the University of Edinburgh have developed a new tool that could help to detect signs of MND in
Reading Time: 4 minutesHello everyone. My name is Genevieve (Gen) and I have joined the Association as Philanthropy Information Officer. One of my roles is to communicate the
Reading Time: 6 minutesOver the past couple of years, the pace of MND research has continued to increase. In the last year alone, we saw an increase in
Reading Time: 6 minutesMND is a very complex disease, and in the UK there is still only one approved treatment so the need for more effective treatments remains
Reading Time: 4 minutesA new clinical trial, investigating Dazucorilant, for the treatment of MND is now open for recruitment in the UK. With this trial, there are now
Reading Time: 7 minutesOn 25th April 2023 Tofersen (now known as Qalsody in the US), a treatment for SOD1 MND was approved by the Food and Drug Administration
Reading Time: 6 minutesOver the last year ALS/MND clinical trials have taken centre stage, with more trials than ever opening for recruitment in the UK, the news of promising results from some trials and the approval of drugs by some regulatory authorities. With the year coming to an end, we thought we would roundup some recent clinical trial updates that were presented at the 33rd International Symposium on ALS/MND.
Reading Time: 5 minutesThe top-line results of the Modifying Immune Response and OutComes in ALS (MIROCALS) clinical trial were announced on 6 December 2022 at the 33rd International Symposium
Reading Time: 6 minutesA recent paper (October 2022), published in the journal Journal of Pathology: Clinical Research suggests that evidence of MND can be seen inside people years before